ID   P388/CPT45
AC   CVCL_D638
SY   P388CPT45; P388/CPT; CPT45
DR   ChEMBL-Cells; CHEMBL3307567
DR   ChEMBL-Targets; CHEMBL614223
DR   PubChem_Cell_line; CVCL_D638
DR   Wikidata; Q54937264
RX   PubMed=2172765;
RX   PubMed=14679002;
CC   Selected for resistance to: ChEBI; CHEBI:27656; Camptothecin (CPT).
CC   Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Breed/subspecies: DBA/2.
DI   NCIt; C21602; Mouse lymphoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_D640 ! P388/S
SX   Female
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 21-03-23; Version: 13
//
RX   PubMed=2172765;
RA   Eng W.K., McCabe F.L., Tan K.B., Mattern M.R., Hofmann G.A.,
RA   Woessner R.D., Hertzberg R.P., Johnson R.K.;
RT   "Development of a stable camptothecin-resistant subline of P388
RT   leukemia with reduced topoisomerase I content.";
RL   Mol. Pharmacol. 38:471-480(1990).
//
RX   PubMed=14679002;
RA   Li T.-K., Houghton P.J., Desai S.D., Daroui P., Liu A.A., Hars E.S.,
RA   Ruchelman A.L., LaVoie E.J., Liu L.F.;
RT   "Characterization of ARC-111 as a novel topoisomerase I-targeting
RT   anticancer drug.";
RL   Cancer Res. 63:8400-8407(2003).
//